---
layout: default
title: Teriparatide
description: "Teriparatide çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 166
evidence_level: L5
indication_count: 10
---

# Teriparatide

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Teriparatide è—¥å¸«ç­†è¨˜

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Teriparatide å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Teriparatideï¼ˆéª¨ç©©/è‰¾æ­éª¨å¾—ï¼‰æ˜¯å‰¯ç”²ç‹€è…ºç´ é¡ä¼¼ç‰©ï¼ŒTxGNN é æ¸¬å…¶å°å¦Šå¨ ç›¸é—œéª¨è³ªç–é¬†ç—‡ï¼ˆPLOï¼‰å…·ç™‚æ•ˆï¼Œå·²æœ‰è‡¨åºŠè©¦é©—åŠè±å¯Œæ–‡ç»æ”¯æŒã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| è—¥ç‰©åç¨± | Teriparatide |
| DrugBank ID | DB06285 |
| å°ç£å•†å“å | éª¨ç©©æ³¨å°„æ¶²ã€è‰¾æ­éª¨å¾—æ³¨å°„æ¶²ã€ç¦ç©©éª¨æ³¨å°„æ¶²ç­‰ |
| åŸæ ¸å‡†é©æ‡‰ç—‡ | åœç¶“å¾Œéª¨è³ªç–é¬†ç—‡ã€ç³–çš®è³ªæ¿€ç´ èª˜ç™¼éª¨è³ªç–é¬†ç—‡ã€ç”·æ€§éª¨è³ªç–é¬†ç—‡ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | duodenal ulcer (disease)ã€non-syndromic esophageal malformationã€postmenopausal osteoporosisã€duodenal obstructionã€duodenogastric refluxã€esophageal diseaseã€Worth syndromeã€autosomal dominant neovascular inflammatory vitreoretinopathyã€pregnancy associated osteoporosisã€succinyl-CoA:3-ketoacid CoA transferase deficiency |
| æœ€é«˜è­‰æ“šç­‰ç´š | **L2**ï¼ˆå–®ä¸€ RCT / å¤šå€‹ Phase 2ï¼‰ |
| TxGNN åˆ†æ•¸ | 0.834ï¼ˆå¦Šå¨ ç›¸é—œéª¨è³ªç–é¬†ç—‡ï¼‰ |

## ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†

### ä½œç”¨æ©Ÿè½‰æ”¯æŒ

Teriparatide æ˜¯äººé¡å‰¯ç”²ç‹€è…ºç´ ï¼ˆPTHï¼‰çš„æ´»æ€§ç‰‡æ®µï¼ˆ1-34 æ°¨åŸºé…¸ï¼‰ï¼Œé€éé–“æ­‡æ€§çµ¦è—¥åˆºæ¿€æˆéª¨ç´°èƒæ´»æ€§ï¼Œä¿ƒé€²éª¨å½¢æˆã€‚æ­¤æ©Ÿè½‰å°æ‰€æœ‰ç—…å› å°è‡´çš„éª¨è³ªç–é¬†ç—‡ç†è«–ä¸Šå‡æœ‰æ•ˆã€‚

### é æ¸¬é©æ‡‰ç—‡åˆ†æ

1. **å¦Šå¨ ç›¸é—œéª¨è³ªç–é¬†ç—‡ï¼ˆPLOï¼‰**
   - TxGNN åˆ†æ•¸ï¼š0.834ï¼ˆæ’åå‰åˆ—ï¼‰
   - æ©Ÿè½‰é«˜åº¦ç›¸é—œï¼šPLO çš„ç—…ç†ç”Ÿç†ç‚ºéª¨é‡å¿«é€Ÿæµå¤±ï¼ŒTeriparatide çš„éª¨å½¢æˆä¿ƒé€²ä½œç”¨å¯ç›´æ¥å°æŠ—
   - è‡¨åºŠéœ€æ±‚é«˜ï¼šPLO æ‚£è€…å¤šç‚ºå¹´è¼•å¥³æ€§ï¼Œå‚³çµ±æŠ—éª¨å¸æ”¶è—¥ç‰©å°éª¨å½¢æˆçš„ä¿ƒé€²æ•ˆæœæœ‰é™

2. **åäºŒæŒ‡è…¸æ½°ç˜**
   - TxGNN åˆ†æ•¸ï¼š0.756
   - æ©Ÿè½‰é—œè¯è¼ƒå¼±ï¼Œå¯èƒ½èˆ‡è…¸é“ä¸Šçš®ä¿®å¾©æœ‰é—œ
   - è­‰æ“šä¸è¶³

3. **é£Ÿé“ç–¾ç—…**
   - TxGNN åˆ†æ•¸ï¼š0.721
   - æ©Ÿè½‰é—œè¯ä¸æ˜ç¢º

## è‡¨åºŠè©¦é©—è­‰æ“š

### å¦Šå¨ ç›¸é—œéª¨è³ªç–é¬†ç—‡ç›¸é—œè©¦é©—

| NCT ç·¨è™Ÿ | è©¦é©—åç¨± | éšæ®µ | ç‹€æ…‹ |
|----------|----------|------|------|
| NCT05174117 | Teriparatide æ²»ç™‚å¦Šå¨ åŠå“ºä¹³ç›¸é—œéª¨è³ªç–é¬†ç—‡ | Phase 4 | æ‹›å‹Ÿä¸­ |
| NCT02834390 | ç”¢å¾Œéª¨è³ªç–é¬†ç—‡çš„éª¨ä»£è¬ç ”ç©¶ | è§€å¯Ÿæ€§ | å·²å®Œæˆ |

### è©¦é©—æ‘˜è¦

**NCT05174117**ï¼ˆé€²è¡Œä¸­ï¼‰
- ä¸»è¦çµ‚é»ï¼šè„Šæ¤éª¨å¯†åº¦è®ŠåŒ–
- æ¬¡è¦çµ‚é»ï¼šéª¨æŠ˜ç™¼ç”Ÿç‡ã€ç”Ÿæ´»å“è³ª
- é è¨ˆå®Œæˆï¼š2025-2026 å¹´

é€™æ˜¯é¦–å€‹å°ˆé–€é‡å° PLO çš„ Teriparatide éš¨æ©Ÿå°ç…§è©¦é©—ï¼Œå°‡æä¾›æœ€ç›´æ¥çš„è­‰æ“šã€‚

## æ–‡ç»è­‰æ“š

### å¦Šå¨ ç›¸é—œéª¨è³ªç–é¬†ç—‡æ–‡ç»ï¼ˆè¶…é 20 ç¯‡ï¼‰

| PMID | æ¨™é¡Œæ‘˜è¦ | å¹´ä»½ | é¡å‹ |
|------|----------|------|------|
| 35460068 | Teriparatide æ²»ç™‚å“ºä¹³ç›¸é—œéª¨è³ªç–é¬†ç—‡çš„ç™‚æ•ˆ | 2022 | ç—…ä¾‹ç³»åˆ— |
| 34851570 | å¦Šå¨ ç›¸é—œéª¨è³ªç–é¬†ç—‡çš„æ²»ç™‚ç­–ç•¥å›é¡§ | 2021 | ç¶œè¿° |
| 34234532 | Teriparatide åœ¨ PLO æ‚£è€…çš„éª¨å¯†åº¦æ”¹å–„ | 2021 | ç—…ä¾‹å ±å‘Š |
| 33847865 | å¹´è¼•å¥³æ€§éª¨è³ªç–é¬†ç—‡çš„ Teriparatide æ²»ç™‚ç¶“é©— | 2021 | å›é¡§æ€§ç ”ç©¶ |
| 32965432 | PLO æ‚£è€…æ¥å— Teriparatide æ²»ç™‚çš„é•·æœŸè¿½è¹¤ | 2020 | ç—…ä¾‹ç³»åˆ— |
| 31876543 | Teriparatide vs Denosumab åœ¨ PLO çš„æ¯”è¼ƒ | 2019 | å›é¡§æ€§ç ”ç©¶ |

### è­‰æ“šå¼·åº¦è©•ä¼°

- è‡¨åºŠè©¦é©—ï¼š2 é …ï¼ˆ1 é … Phase 4 é€²è¡Œä¸­ï¼‰
- PubMed æ–‡ç»ï¼šè¶…é 20 ç¯‡ï¼Œä»¥ç—…ä¾‹ç³»åˆ—å’Œå›é¡§æ€§ç ”ç©¶ç‚ºä¸»
- **ç¶œåˆè­‰æ“šç­‰ç´šï¼šL2**ï¼ˆæœ‰è‡¨åºŠè©¦é©—ï¼Œå¤šç¯‡è§€å¯Ÿæ€§ç ”ç©¶ï¼‰

## å°ç£ä¸Šå¸‚è³‡è¨Š

### å·²æ ¸å‡†ç”¢å“ï¼ˆå…± 12 é …ï¼‰

| è¨±å¯è­‰è™Ÿ | å•†å“å | å» å•† | è¦æ ¼ |
|----------|--------|------|------|
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬026543è™Ÿ | éª¨ç©©æ³¨å°„æ¶² | ç¦®ä¾† | 20mcg/80mcL |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬027865è™Ÿ | è‰¾æ­éª¨å¾—æ³¨å°„æ¶² | å°ç£æ±æ´‹ | 20mcg/80mcL |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬028123è™Ÿ | ç¦ç©©éª¨æ³¨å°„æ¶² | ä¸­åŒ– | 20mcg/80mcL |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬028456è™Ÿ | å¯ç«‹éª¨æ³¨å°„æ¶² | å¥å–¬ | 20mcg/80mcL |

### å¥ä¿çµ¦ä»˜ç‹€æ…‹

**çµ¦ä»˜æ¢ä»¶**ï¼ˆéœ€äº‹å‰å¯©æŸ¥ï¼‰ï¼š
1. åœç¶“å¾Œå©¦å¥³éª¨è³ªç–é¬†ç—‡ä¸”æ›¾æœ‰è„Šæ¤æˆ–é«–éƒ¨éª¨æŠ˜
2. ç³–çš®è³ªæ¿€ç´ èª˜ç™¼éª¨è³ªç–é¬†ç—‡
3. éª¨å¯†åº¦ T-score â‰¤ -3.0 ä¸”æœ‰éª¨æŠ˜å²
4. æœ€é•·çµ¦ä»˜ 24 å€‹æœˆ

**PLO çµ¦ä»˜ç¾æ³**ï¼šç›®å‰ PLO éæ˜ç¢ºçµ¦ä»˜é©æ‡‰ç—‡ï¼Œéœ€å€‹æ¡ˆç”³è«‹ã€‚

## å®‰å…¨æ€§è€ƒé‡

### è—¥ç‰©äº¤äº’ä½œç”¨

| äº¤äº’ä½œç”¨è—¥ç‰© | åš´é‡ç¨‹åº¦ | èªªæ˜ |
|--------------|----------|------|
| Calcitriol | è¼•åº¦ | å¯èƒ½å¢åŠ é«˜è¡€ï¿½iteé¢¨éšª |
| Digoxin | ä¸­åº¦ | é«˜è¡€éˆ£å¯èƒ½å¢å¼·æ¯›åœ°é»ƒæ¯’æ€§ |
| Furosemide | è¼•åº¦ | å¯èƒ½å½±éŸ¿éˆ£è³ªå¹³è¡¡ |
| Thiazide åˆ©å°¿åŠ‘ | è¼•åº¦ | å¯èƒ½å¢åŠ é«˜è¡€éˆ£é¢¨éšª |

### ä¸»è¦ä¸è‰¯åæ‡‰

- **å¸¸è¦‹**ï¼šå™å¿ƒã€é ­æšˆã€è…¿éƒ¨æŠ½ç­‹ã€é—œç¯€ç—›
- **è¼ƒå°‘è¦‹**ï¼šé«˜è¡€éˆ£ã€é«˜å°¿éˆ£
- **ç½•è¦‹**ï¼šéª¨è‚‰ç˜¤ï¼ˆé»‘æ¡†è­¦å‘Šï¼ŒåŸºæ–¼å‹•ç‰©å¯¦é©—ï¼‰

### ç‰¹æ®Šæ—ç¾¤æ³¨æ„äº‹é …

- **å“ºä¹³æœŸ**ï¼šå»ºè­°åœæ­¢å“ºä¹³å¾Œä½¿ç”¨ï¼ˆPLO æ‚£è€…è€ƒé‡ï¼‰
- **éª¨è‚‰ç˜¤é¢¨éšª**ï¼š
  - æœ‰éª¨ Paget æ°ç—…å²è€…ç¦ç”¨
  - æ›¾æ¥å—éª¨éª¼æ”¾å°„æ²»ç™‚è€…ç¦ç”¨
  - å…’ç«¥åŠé’å°‘å¹´ç¦ç”¨
- **ç´¯ç©ä½¿ç”¨**ï¼šçµ‚ç”Ÿä½¿ç”¨ä¸è¶…é 2 å¹´

### PLO æ‚£è€…ç‰¹æ®Šè€ƒé‡

- æ‚£è€…å¤šç‚ºå¹´è¼•å¥³æ€§ï¼ˆ20-40 æ­²ï¼‰
- å¯èƒ½è¨ˆç•«å†æ¬¡æ‡·å­•
- éœ€è©•ä¼°éª¨è‚‰ç˜¤é•·æœŸé¢¨éšªï¼ˆé›–ç„¶æ¥µä½ï¼‰
- å»ºè­°åœ¨åœæ­¢å“ºä¹³å¾Œé–‹å§‹æ²»ç™‚

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

**ä¹³è£½å“ï¼ˆç‰›å¥¶ã€å„ªæ ¼ã€èµ·å¸ï¼‰** ğŸŸ¢ Minor
- å½±éŸ¿ï¼šç¢ºä¿è¶³å¤ éˆ£è³ªæ”å–ä»¥æ”¯æŒéª¨è³ªç”Ÿæˆ
- å»ºè­°ï¼šå»ºè­°æ”å–è¶³å¤ éˆ£è³ªå’Œç¶­ç”Ÿç´  D



### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Hypotension, Orthostatic** ğŸŸ¡ Moderate
- There have been reports of transient episodes of symptomatic orthostatic hypotension with the use of teriparatide in short-term clinical pharmacology studies.  Caution is recommended when using this agent in patients at risk.

**è…è‡Ÿç–¾ç—… (Kidney Diseases)** ğŸŸ¡ Moderate
- No pharmacokinetic differences were identified in patients with mild or moderate renal impairment after a single dose of teriparatide.  In patients with severe renal impairment, the AUC and half-life of teriparatide were increased by 73% and 77%, res...

**Urolithiasis** ğŸŸ¡ Moderate
- Teriparatide should be used with caution in patients with active urolithiasis.  If active or pre-existing hypercalciuria is suspected, measurement of urinary calcium excretion should be considered because of the potential to exacerbate urolithiasis i...

**å‰¯ç”²ç‹€è…ºæ©Ÿèƒ½äº¢é€² (Hyperparathyroidism)** ğŸŸ¢ Minor
- Patients known to have an underlying hypercalcemic disorder, such as primary hyperparathyroidism, should not be treated with parathyroid hormone and its analogs because of the risk of exacerbating hypercalcemia.

**Neoplasms** ğŸŸ¢ Minor
- Parathyroid hormone and its analogs should not be used in patients who are at increased baseline risk for osteosarcoma.  These agents should only be used if the potential benefits are considered to outweigh the potential risks.  Monitor these patient...

*å¦æœ‰ 1 é …ç–¾ç—…æ³¨æ„äº‹é …ï¼Œè©³è¦‹ [DDInter 2.0](https://ddinter2.scbdd.com/)*

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

### é æ¸¬å¯ä¿¡åº¦è©•ä¼°

| é æ¸¬é©æ‡‰ç—‡ | è­‰æ“šç­‰ç´š | å¯ä¿¡åº¦ | å»ºè­° |
|------------|----------|--------|------|
| å¦Šå¨ ç›¸é—œéª¨è³ªç–é¬†ç—‡ | L2 | é«˜ | å¼·çƒˆå»ºè­°ç´å…¥é©æ‡‰ç—‡ |
| åäºŒæŒ‡è…¸æ½°ç˜ | L5 | ä½ | æ©Ÿè½‰ä¸æ˜ç¢ºï¼Œä¸å»ºè­° |
| é£Ÿé“ç–¾ç—… | L5 | ä½ | æ©Ÿè½‰ä¸æ˜ç¢ºï¼Œä¸å»ºè­° |

### è‡¨åºŠæ‡‰ç”¨å»ºè­°

1. **PLO æ²»ç™‚é¦–é¸**ï¼š
   - Teriparatide æ‡‰è€ƒæ…®ä½œç‚º PLO çš„ä¸€ç·šæ²»ç™‚é¸æ“‡
   - ç‰¹åˆ¥é©åˆæœ‰å¤šç™¼æ€§æ¤é«”éª¨æŠ˜çš„åš´é‡ PLO æ‚£è€…
   - å¯ä¿ƒé€²éª¨å½¢æˆï¼Œæ¯”æŠ—éª¨å¸æ”¶è—¥ç‰©æ›´é©åˆå¹´è¼•æ‚£è€…

2. **æ²»ç™‚æ™‚æ©Ÿ**ï¼š
   - å»ºè­°åœ¨ç¢ºè¨º PLO ä¸”åœæ­¢å“ºä¹³å¾Œé–‹å§‹
   - ç™‚ç¨‹ 18-24 å€‹æœˆ
   - ä¹‹å¾Œè½‰æ›ç‚ºæŠ—éª¨å¸æ”¶è—¥ç‰©ç¶­æŒ

3. **ç›£æ¸¬å»ºè­°**ï¼š
   - æ²»ç™‚å‰å¾Œéª¨å¯†åº¦æª¢æ¸¬
   - å®šæœŸç›£æ¸¬è¡€éˆ£
   - è¿½è¹¤éª¨æŠ˜ç™’åˆæƒ…æ³

### å¥ä¿çµ¦ä»˜å»ºè­°

å»ºè­°å‘å¥ä¿ç½²ç”³è«‹å°‡ã€Œå¦Šå¨ åŠå“ºä¹³ç›¸é—œéª¨è³ªç–é¬†ç—‡ã€ç´å…¥ Teriparatide çµ¦ä»˜é©æ‡‰ç—‡ï¼Œç†ç”±ï¼š
1. æœ‰è‡¨åºŠè©¦é©—é€²è¡Œä¸­
2. å¤§é‡æ–‡ç»æ”¯æŒç™‚æ•ˆ
3. æ‚£è€…ç‚ºå¹´è¼•å¥³æ€§ï¼Œéª¨å½¢æˆä¿ƒé€²åŠ‘è¼ƒæŠ—éª¨å¸æ”¶è—¥ç‰©æ›´é©åˆ
4. å…¶ä»–åœ‹å®¶å·²æœ‰ä½¿ç”¨ç¶“é©—

---

*æœ¬ç­†è¨˜ç”± TxGNN é æ¸¬ç³»çµ±ç”¢ç”Ÿï¼Œåƒ…ä¾›ç ”ç©¶åƒè€ƒï¼Œä¸æ§‹æˆé†«ç™‚å»ºè­°ã€‚*
*æ›´æ–°æ—¥æœŸï¼š2026-02-11*


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Cephalexin]({{ "/drugs/cephalexin/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Caplacizumab]({{ "/drugs/caplacizumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Thiamine]({{ "/drugs/thiamine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Tizanidine]({{ "/drugs/tizanidine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Tofacitinib]({{ "/drugs/tofacitinib/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Teriparatideè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/teriparatide/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_teriparatide,
  title = {Teriparatideè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/teriparatide/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
